This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Press ReleasesVideo MaterialAwardsScientific PublicationsRelated LinksSubscription Press MailingMedia Contact

Press Releases Detail

ITM Isotope Technologies Munich to Present at the 40th Annual J.P. Morgan Healthcare Conference

Garching / Munich, January 5, 2022 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10.30am ET (4.30pm CET).

- End -

 

 

 

 

About ITM Isotope Technologies Munich SE
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline, including two phase III studies, combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

For more information please visit: www.itm-radiopharma.com.

 

ITM Contact

Corporate Contact 
Julia Hofmann / Susanne Karlsson
Corporate Communications
Phone: +49 89 329 8986 1502                 
Email: communications(at)itm-radiopharma.com

Investor Contact
Ben Orzelek 
Investor Relations 
Phone: +49 89 329 8986 1009                 
Email: Ben.Orzelek(at)itm-radiopharma.com

ITM Media Requests
Trophic Communications
Stephanie May or Valeria Fisher
Phone: +49 171 185 56 82
Email: itm(at)trophic.eu